Great list of clinical and pre-clinical trials forthcoming, and certainly a list to keep and refer to. Thank you.
Currently, either the market does not believe the arbitrage argument about the PolyMedix acquisition, is waiting for more specified lab results from P1 K trial, or is "saying" that in general, potential and promise do not count in baby bio-techs.